Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Chart Extraction/Clinician Survey Shows Symptom Impact and Favorable Treatment Outcomes with VMAT2 Inhibitors in Patients with Tardive Dyskinesia
Movement Disorders
P6 - Poster Session 6 (12:00 PM-1:00 PM)

Based on clinical studies for two approved VMAT2 inhibitors (valbenazine, deutetrabenazine), these medications are recommended as first-line therapies for TD (Bhidayasiri, J Neurol Sci 2018). Data based on real-world experience with these drugs are now available.

To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine transporter 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD).

From 24-Jul-2019 to 30-Aug-2019, clinicians who prescribed a VMAT2 inhibitor within the past 24 months were invited to complete a survey and provide charts of 1-10 TD patient(s) for data extraction. The clinician survey included questions regarding TD symptomatology and impact, psychiatric condition (primary and comorbid), and treatment outcomes. Data extracted from patients’ charts included demographics, treatment with a VMAT2 inhibitor (valbenazine, deutetrabenazine, tetrabenazine), and antipsychotic treatment.

Data for 601 adult TD patients were provided by 163 responding clinicians (113 psychiatrists; 46 neurologists; 4 primary care physicians). 50% of patients were male; mean age was 50.6 years; and most were taking an antipsychotic for schizophrenia (32%), bipolar disorder (29%), schizoaffective disorder (23%), and/or major depressive disorder (11%). Approximately two-thirds of patients had an additional psychiatric comorbidity, including anxiety (33%), depressive symptoms (28%), and substance abuse (18%). TD symptoms were most frequently found in the head/face/mouth region (82%). TD impacts included negative effects on socializing (84%) and engagement with family/friends (77%). TD symptom improvement with a VMAT2 inhibitor was reported in 540 (90%) patients, most of whom also had functional improvements in ≥1 area. Among patients with TD improvement, 374 (69%) had “much” or “significant” improvement in their psychiatric condition.

In this real-world sample of patients, treatment with a VMAT 2 inhibitor improved TD symptoms and TD-related outcomes. These improvements also appeared to be associated with better psychiatric status. Clinicians/payers/professional organizations should consider symptom impact and treatment outcomes when evaluating TD therapies.

Chuck Yonan
Chuck Yonan has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Leslie Lundt Leslie Lundt has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Ericha Franey Ericha Franey has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.. Ericha Franey has received stock or an ownership interest from Ericha Franey.